Our systematic evaluation ensures that all necessary regulatory information is complete, accurate, and aligned with the latest standards and guidelines. By thoroughly assessing your files, we help you proactively address any deficiencies or omissions, thereby enhancing the quality of your submission and increasing the likelihood of obtaining marketing approval. This not only streamlines the approval process but also minimizes the risk of delays or rejections due to regulatory non-compliance.
What can we do for you?
Our team of experts brings extensive experience in evaluating a variety of regulatory documentation, for all aspects of drug development (non-clinical, clinical and CMC) and during all phases of development (clinical phases, MAA/BLA and post-approval).
We provide you with an extensive gap and risk assessment report including a SWOT analysis (strengths, weaknesses, opportunities, and threats).
Approach & Expertise
Learn how we can support you in meeting your business goals
- Our lean and powerful team with degrees in pharmacy, chemistry, biology, or related studies strive to be of added value to you. Our short reporting lines enable the most efficient road to your success.
- Having one point of contact from our experts backed by the team’s collective knowledge and resources we give reliable advice and execute projects seamlessly.
- At Starodub, consistency and assurance of quality are vital. A quality management system has been implemented and we adhere to GxP and ISO 9001/13485.
Questions from our clients
FAQ Section
Gap assessments are crucial to identify any deficiencies or risks in regulatory compliance. By conducting thorough assessments, companies can mitigate compliance risks, ensure product quality and safety, and avoid regulatory issues that could delay approvals or lead to costly remediation efforts.
Failing to conduct a thorough gap assessment can result in several negative consequences, including:
- Delayed Approvals: Regulatory authorities may request additional information or clarification, causing delays.
- Rejection of the Dossier: Significant deficiencies or non-compliance issues may lead to outright rejection.
- Increased Costs: Additional time and resources will be needed to address issues post-submission, increasing overall costs.
- Regulatory Scrutiny: Poorly prepared dossiers can attract more stringent reviews in future submissions.
- Risk to Market Entry: Delays or rejections can affect the product’s time-to-market, impacting competitive advantage and revenue.